Saturday, November 7, 2026

GENITAL WART

Genital Warts
Swaraj Hospital logo
SWARAJ HOSPITAL & RESEARCH INSTITUTE
BOLANGIR, ODISHA  •  OBSTETRICS & GYNAECOLOGY CLINICAL PATHWAY SERIES
Clinician Reference Infographic

Genital Warts — Recognise, Treat & Counsel

Genital warts are common, caused by HPV and not dangerous in themselves. This sheet gives how to recognise them, what else to exclude, how to choose treatment, and how to counsel, including in pregnancy.

Genital warts (also called anogenital warts) are skin growths caused by human papillomavirus (HPV); most are due to types 6 and 11, which are low-risk types that do not usually cause cancer (BASHH)

They spread by skin-to-skin contact during vaginal, anal or oral sex, and by sharing sex toys; not by towels, baths, toilet seats or swimming pools

Warts may appear weeks, months or years after infection (average 3 to 11 months), so the time of infection and the source usually cannot be known

About 10 to 20% of patients have another sexually transmitted infection, so test for HIV, syphilis, chlamydia and gonorrhoea (Sandyford)

The diagnosis is made by looking; acetic acid testing for hidden infection is not recommended

Treatment clears the visible warts; no treatment is 100% effective and warts often return; some clear without treatment

Look carefully, test for other infections, biopsy anything that does not look typical, and counsel her kindly: warts are common and not a sign of cancer or of unfaithfulness.
ЁЯЪи DO NOT JUST TREAT — BIOPSY OR REFER IF…
The lesion is pigmented, hard, fixed, ulcerated, bleeding or otherwise unusual — biopsy to exclude vulval pre-cancer (VIN) or cancer before treating (from memory)
The diagnosis is uncertain — seek a senior opinion; a biopsy may be needed if warts look unusual
Warts are large, extensive or do not respond to a full course — refer for surgical removal or laser
She is immunosuppressed (HIV, transplant, long steroids, chemotherapy) — warts are more persistent; consider excision and keep a low threshold for biopsy (from memory)
Warts inside the urethra, vagina, cervix or anus — examine with a speculum or proctoscope as indicated; urethral warts not fully seen need referral
A child has anogenital warts — think of sexual abuse, though warts can also pass from mother to baby at birth; follow child-protection procedures (from memory)
STEP 1 · RECOGNISE — what it looks like, and what else it may be
ЁЯФН WHAT GENITAL WARTS LOOK LIKE

Skin-coloured, pink or brownish lumps; soft, rough or cauliflower-like, or flat and slightly raised

On the labia, around the vaginal opening and perineum, and around the anus; sometimes inside the vagina, at the urethral opening or on the cervix

Usually painless; some women have itching, soreness or bleeding, and many have no symptoms and notice a lump

They often grow and multiply during pregnancy

Document the site, number, size, whether the surface is keratinised, and any pigment; note pregnancy and whether she can return for treatment (Sandyford)

Look-alikeHow it differs
Vestibular papillae (normal)Tiny, even, finger-like projections in a symmetrical band at the vaginal opening; no treatment needed (from memory)
Molluscum contagiosumSmooth, firm, dome-shaped papules, often with a central dimple (from memory)
Condylomata lata (secondary syphilis)Broad, flat, moist, grey-white plaques; send syphilis serology (from memory)
Skin tagsSoft, smooth and often on a thin stalk (from memory)
Vulval pre-cancer or cancerPigmented, raised, ulcerated or bleeding; persistent; older women and smokers; biopsy (from memory)
ЁЯй║ AT THE FIRST VISIT

Examine in good light; use a speculum only if internal warts are suspected, and a proctoscope only for anal symptoms

Offer HIV, syphilis, and chlamydia and gonorrhoea tests

Check for pregnancy before choosing treatment (from memory)

Do not do HPV typing of the warts; warts do not change the usual cervical screening schedule, because the types that cause warts differ from those that cause cervical cancer

Ask about distress: a diagnosis can be upsetting, and support can be arranged

STEP 2 · TREAT — choose by site, number, pregnancy and what she can do at home
From the first look to the choice of treatmentWoman with lumps on the vulva or perineumAsk about duration, bleeding, pregnancy, immunityExamine in good light; speculum if inside the vaginaOffer HIV, syphilis, chlamydia and gonorrhoea testsTypical wartsSkin-coloured, papillary, often severalAtypical or doubtfulPigmented, hard, ulcerated, bleeding, fixedIs she pregnant?Pregnancy changes the choice of treatmentBiopsy first, then referExclude VIN and cancer before any treatmentPregnantCryotherapy or TCANo creamsNot pregnantHome cream, orcryotherapy in clinicAfter any treatmentReview every 2–4 weeksChange if under half cleared by 4–8 weeksTreatment regimens, pregnancy advice and referral points are from the BASHH and Sandyford guidance.Biopsy criteria and use of TCA in pregnancy are from memory.
ЁЯТК TREATMENT OPTIONS
TreatmentHow it is usedKey points
Podophyllotoxin 0.5% solution or 0.15% cream
(she applies it)
Twice a day for 3 days, then 4 days rest; up to 4 cycles; review at 4 weeksClears 40 to 70%; irritation is common; avoid on broken skin and in pregnancy
Imiquimod 5% cream
(she applies it)
Three nights a week; wash off after 6 to 10 hours; until clear, at most 16 weeksSkin reactions are common; avoid in pregnancy; caution with autoimmune disease or transplant
Green tea extract (sinecatechins) ointment
(she applies it)
Three times a day, up to 16 weeksNot for the vagina, urethra or anus; wash off before sex; avoid in pregnancy and breastfeeding
Cryotherapy (liquid nitrogen)
(clinic)
Freeze, thaw, freeze again, 10 to 20 seconds each; every 1 to 2 weeksTreatment of choice in pregnancy and for warts at the urethral opening; not suited to large or clustered warts
Trichloroacetic acid 80–90%
(specialist)
Applied sparingly once a week; consider another option if under half have cleared after 4 applicationsSpecialist-applied; usually accepted in pregnancy (from memory)
Surgery or laser
(specialist)
For large, extensive or resistant wartsDone under anaesthesia where needed; consider early if she is immunosuppressed
Tips: Show her how to apply the cream and exactly where. Avoid sex just after treatment because of irritation. Stop and review if there is severe pain or a spreading sore. Smokers respond less well, so advise stopping.
STEP 3 · SPECIAL SITUATIONS AND COUNSELLING — what she needs to hear

Warts may appear or grow during pregnancy; treatment is possible but she should not use podophyllotoxin, imiquimod or green tea ointment; cryotherapy is preferred

HPV and warts cannot pass to the baby before birth; rarely a baby is infected during delivery

Warts alone are not a reason for caesarean section; she should tell the antenatal team (BASHH; caesarean is considered only if they block the birth canal, from memory)

ЁЯЧг️ WHAT TO TELL HER AND HER PARTNER

Warts are very common; the virus often clears by itself; having warts does not by itself mean a weak immune system

She cannot tell when or from whom she was infected, and the position of the warts does not show how they were caught

Her partner needs treatment only if he or she has warts; partners may attend for a check or sexual health screening; treating partners does not change the course of her warts

Condoms cut the chance of catching HPV and warts by about 30 to 60%, but only cover the skin they touch; warts are most infectious when visible, so waiting until they clear lowers the risk

Warts can come back, especially in smokers, in pregnancy, and in immunosuppressed women

HPV vaccines that include types 6 and 11 prevent warts well when given before exposure; it is not yet known whether they clear existing warts; ask which vaccine is available in your area (from memory)

Vaccination, ideally before first sex

Condoms from the start of every sexual relationship

Not smoking, which makes HPV infection more likely and treatment less effective

Keep to the national cervical screening schedule (VIA every 5 years from age 30 to 65 in India)

⚠️ COMMON PITFALLS

Treating without testing for other infections

Giving podophyllotoxin, imiquimod or green tea ointment in pregnancy

Treating a pigmented, ulcerated or bleeding lesion without a biopsy

Putting creams inside the vagina, urethra or anus when the product is not meant for it

Home remedies such as acids, caustic pastes or cutting the lumps, which burn and scar (from memory)

Telling her that warts mean cancer, or that her partner has been unfaithful

Saying she is cured for life, or forgetting cervical screening

Missing the possibility of abuse when a child has warts

Memory Aid

WARTS

Five steps for genital warts.
W
Work up — test for HIV, syphilis, chlamydia and gonorrhoea
A
Assess by sight — biopsy anything atypical
R
Right treatment — by site, number and pregnancy
T
Tell and counsel — partners, condoms, recurrence
S
Shield — vaccine, cervical screening, stop smoking
Remember: warts are common, treatable and not cancer; look carefully, treat gently and explain clearly.

Friday, November 6, 2026

shriwomenhealthwellness/caring-for-every-woman-at-every-stage.

Knowledge is power. Scan for the health guide every woman needs." Small initiative to empower womanhood. ЁЯЩП

 No photo description available.

Ovarian Cancer

Swaraj Hospital logo
SWARAJ HOSPITAL & RESEARCH INSTITUTE
BOLANGIR, ODISHA  •  OBSTETRICS & GYNAECOLOGY CLINICAL PATHWAY SERIES
Clinician Reference Infographic

Ovarian Cancer — Early Recognition to Targeted Treatment

Ovarian cancer is usually found late. This sheet gives who is at risk, the symptoms that should trigger a CA125 test, diagnosis and staging, treatment, and genetic testing.

Ovarian cancer is often found late, because early disease is usually silent and later symptoms are vague

Five-year survival is under 50% overall: about 92% for stage I epithelial cancer, and 17–28% for stage IV (AAFP 2016)

Age and family history are the strongest risks; BRCA mutations cause about 10% of cases and Lynch syndrome 2–3%

Symptoms that are persistent or frequent, especially bloating, early fullness, pelvic pain and urinary urgency, should prompt a CA125 test

There is no routine screening of women without symptoms; USPSTF and AAFP advise against it

Treatment is surgery by a gynae-oncology team plus platinum chemotherapy; BRCA and HRD testing guide maintenance with PARP inhibitors

Think of ovarian cancer in any woman with new, persistent abdominal symptoms: test CA125, scan, and refer early.
ЁЯЪи TEST AT ONCE OR REFER IF…
Persistent or frequent bloating, early fullness, loss of appetite, pelvic or abdominal pain, or urinary urgency, especially over 50 — measure CA125
New bowel symptoms resembling IBS in a woman of 50 or over — test for ovarian cancer too
Ascites, or a pelvic or abdominal mass that is not obviously fibroids — suspected cancer pathway referral
CA125 of 35 IU/ml or more — pelvic and abdominal ultrasound
RMI I of 250 or more — refer to the specialist multidisciplinary team
STEP 1 · WHO IS AT RISK — and how to lower it
⚖️ RISK FACTORS AND PREVENTION
Raises riskLowers risk
Older age, family history of ovarian or breast cancerOral contraceptives for 4 years or more: about 50% lower risk, including in BRCA carriers
BRCA1 (lifetime risk about 40%), BRCA2 (about 18%), Lynch syndromeTubal ligation, salpingectomy, breastfeeding, depot medroxyprogesterone
Hormone therapy after menopause for more than 5 years, obesity or weight gainRisk-reducing bilateral salpingo-oophorectomy in BRCA carriers: 69–100% lower risk
Source: AAFP 2016. Risk-reducing surgery causes premature menopause; counsel her first. Women with a strong family history should be offered genetic counselling.
STEP 2 · RECOGNISE AND DIAGNOSE — symptoms, CA125, scan
Suspected ovarian cancer: the primary-care pathwayPersistent or frequent bloating, early fullness, pelvic pain, urinary urgencyEspecially over 50, or more than 12 days a month; examine the abdomen and pelvisSerum CA125Under 40 years: also AFP and beta-hCG (secondary care)CA125 below 35 IU/mlLook for other causesCA125 35 IU/ml or morePelvic and abdominal ultrasoundSymptoms persist or worsen?Review again; do not close the caseSuspicious scan, mass or ascites?Suspected cancer pathway; RMI I 250+ to MDTTissue diagnosis, then CTSurgery by the gynae-oncology teamPathway and CA125 threshold are from NICE CG122. CA125 is raised in only about 50% of early cancers and also inendometriosis and fibroids, so a normal result does not exclude cancer. Local protocols differ.
ЁЯФм THE TESTS: WHAT EACH ONE TELLS YOU

CA125: raised in about 80% of epithelial cancers, but only about 50% of early ones; endometriosis and fibroids also raise it

Ultrasound is the first imaging test; CT of the abdomen and pelvis shows the extent of disease; MRI is not routine

Risk of Malignancy Index I (RMI I) combines ultrasound features, menopausal status and CA125; 250 or more means referral to the specialist team (formula from memory)

Under 40 years: also measure AFP and beta-hCG, because germ cell tumours occur in young women

Get a tissue diagnosis before chemotherapy, by image-guided or laparoscopic biopsy, except in rare cases agreed by the MDT

STEP 3 · TYPE AND STAGE — tubo-ovarian cancer, FIGO
Stage (FIGO)Spread
IConfined to the ovaries or fallopian tubes (from memory)
IISpread within the pelvis (from memory)
IIISpread to the peritoneum beyond the pelvis, or to retroperitoneal nodes (from memory)
IVDistant spread: pleural fluid with malignant cells, liver or spleen parenchyma, or distant organs (from memory)

Most cancers are epithelial; high-grade serous carcinoma is the commonest type (from memory)

Sex cord–stromal tumours often cause hormonal effects, such as virilisation, and are usually found at stage I

The FIGO staging definitions were not checked against a fetched source.
STEP 4 · TREAT — surgery, chemotherapy, maintenance

Surgery aims to remove all visible disease; women with suspected ovarian cancer should be operated on by a gynae-oncology team

Early stage I: staging includes retroperitoneal lymph node assessment but not systematic lymphadenectomy

Adjuvant chemotherapy: none for low-risk stage I (grade 1–2, stage IA or IB); six cycles of carboplatin for high-risk stage I (grade 3 or stage IC) (NICE)

Advanced disease: surgery and platinum-based chemotherapy; chemotherapy first with interval surgery is used when complete removal is not possible (from memory)

Intraperitoneal chemotherapy only within clinical trials; combined intraperitoneal and intravenous chemotherapy improved median survival by about 12 months in one review (AAFP 2016)

ЁЯзм GENETIC TESTING AND MAINTENANCE

Test every woman with high-grade ovarian cancer for BRCA1 and BRCA2 (germline or somatic) at diagnosis, and test for HRD (ESMO)

BRCA-mutated and responding to platinum: olaparib for 2 years or niraparib for 3 years

HRD-positive and responding: olaparib with bevacizumab if bevacizumab was started, or niraparib alone

HRD-negative: adding olaparib to bevacizumab is not recommended; niraparib is decided case by case

Her relatives may carry the same gene: offer genetic counselling and cascade testing (from memory)

Primary care helps with surveillance after treatment, and with palliative and end-of-life care

Review symptoms, and refer any return of bloating, pain or a new mass promptly (follow-up interval from memory)

Palliative care early for advanced or recurrent disease; manage ascites, bowel obstruction and pain (from memory)

⚠️ COMMON PITFALLS

Putting symptoms down to irritable bowel or ageing, and not testing

Treating a normal CA125 as proof that there is no cancer, when about half of early cancers have a normal level

Drawing blood for CA125 but not arranging the ultrasound when it is 35 or more

Operating on a suspicious mass outside a gynae-oncology team, which can spill tumour and leave staging incomplete (from memory)

Starting chemotherapy without a tissue diagnosis

Not offering BRCA testing and genetic counselling

Memory Aid

OVARY

Five steps for ovarian cancer.
O
Observe persistent symptoms — bloating, early fullness, pain, urinary urgency
V
Value CA125 and ultrasound — 35 IU/ml or more needs a scan
A
Ascites or a mass — refer on the suspected cancer pathway
R
Resect and give platinum — surgery by the gynae-oncology team
Y
Your genes — BRCA and HRD testing; counsel the family
Remember: vague symptoms that persist deserve a test, not reassurance.

Thursday, November 5, 2026

Endometrial Cancer

Endometrial Cancer
Swaraj Hospital logo
SWARAJ HOSPITAL & RESEARCH INSTITUTE
BOLANGIR, ODISHA  •  OBSTETRICS & GYNAECOLOGY CLINICAL PATHWAY SERIES
Clinician Reference Infographic

Endometrial Cancer — From Postmenopausal Bleeding to Treatment

Endometrial cancer is found early because it bleeds. This sheet gives who is at risk, the work-up of postmenopausal bleeding, molecular classification and staging, treatment, and follow-up.

Endometrial cancer is cancer of the lining of the uterus; it most often presents early with postmenopausal bleeding

Most cases are type I (endometrioid), linked to unopposed estrogen; type II (serous or clear cell) is about 10% of cases but causes about 40% of deaths (AAFP 2016)

Between 5% and 20% of women evaluated for postmenopausal bleeding have cancer (5–10% in one guideline, 10–20% in another); atrophy is the commonest cause, but every woman must be investigated

Diagnosis is by tissue: transvaginal ultrasound selects who needs a biopsy, and the biopsy or hysteroscopy gives the diagnosis

Treatment is usually total hysterectomy with bilateral salpingo-oophorectomy and staging; adjuvant treatment now follows risk group and molecular type

There is no screening test for women at average risk; women with Lynch syndrome are the exception

Any bleeding after menopause is cancer until proven otherwise: scan, sample, and do not stop at one normal result if it recurs.
ЁЯЪи INVESTIGATE AT ONCE OR REFER IF…
Any postmenopausal bleeding, however light, even a single episode
Abnormal uterine bleeding in a woman over 45, or a younger woman with long unopposed estrogen exposure (obesity, PCOS) — needs endometrial sampling
Bleeding recurs, or persists after a normal scan or negative biopsy — hysteroscopy and biopsy, whatever the thickness
Any abnormal bleeding on tamoxifen — thickness correlates poorly with pathology; full evaluation
Biopsy shows atypical hyperplasia or cancer — refer to the gynae-oncology team before any surgery
STEP 1 · WHO IS AT RISK — and what she reports
⚖️ RISK FACTORS AND PROTECTORS
Raises riskLowers risk
Unopposed estrogen therapy, early menarche, late menopause, nulliparity, infertility or anovulation, PCOS, tamoxifenCombined oral contraceptive use for one year or more
Obesity, diabetes, hypertension, thyroid disease, age over 50Grand multiparity
Family history, and Lynch syndrome (lifetime risk 22–50%)Adding progesterone to hormone therapy (AAFP 2016)
Source: AAFP 2016. Managing obesity, diabetes and hypertension may reduce risk.
STEP 2 · DIAGNOSE — scan, sample, confirm
Postmenopausal bleeding: the work-up pathwayBleeding 12 months or more after the last periodEvery woman needs evaluation; examine the cervix tooTransvaginal ultrasound: endometrial thicknessOn HRT the cut-off is 4 mm (continuous) or 7 mm (sequential)4 mm or lessReassure; return if bleeding recursMore than 4 mm, or cannot be measuredPipelle biopsy, or hysteroscopyBleeding recurs, or a risk factor?Do not stop here: hysteroscopy and biopsyBiopsy inadequate, or bleeding persists?Hysteroscopy with directed biopsyCancer or atypical hyperplasiaRefer to the gynae-oncology teamThresholds and pathway are from the NHS Lanarkshire guideline; about 1% of cancers are missed at 4 mm or less,so recurrent bleeding must be reinvestigated. Local protocols differ.
ЁЯФм THE TESTS: WHAT EACH ONE TELLS YOU

Transvaginal ultrasound: above 4–5 mm in a postmenopausal woman, tissue sampling is needed, especially with bleeding; MRI helps when ultrasound is inconclusive; CT and PET are not for initial work-up

Pipelle biopsy: first-line when the sample is adequate; a positive result gives about an 82% probability of cancer, a negative one about 1%; samples are often inadequate

Hysteroscopy: the gold standard for focal lesions that sampling can miss; sensitivity 99%, specificity 86%

If the sample is inadequate or symptoms persist, do hysteroscopy with directed biopsy or D&C

Anticoagulants need not be stopped for Pipelle or diagnostic hysteroscopy

STEP 3 · CLASSIFY AND STAGE — grade, molecular type, FIGO 2023
TypeOutlookAdjuvant approach
POLEmutBest prognosisStage I–II: no adjuvant treatment; evidence lacking for stage III–IV
MMRd (mismatch repair deficient)IntermediateBy stage and risk: none, vaginal brachytherapy, pelvic radiotherapy or chemoradiotherapy
NSMP (no specific profile)Variable; oestrogen-receptor positive is betterEarly stage as for MMRd; not one uniform group
p53abn (abnormal p53)PoorChemoradiotherapy for stage II and above; test HER2
Tested with p53 and mismatch-repair immunohistochemistry plus POLE sequencing. A p53 mutation in a POLEmut or MMRd tumour does not by itself mean more treatment. Sources: Gynecol Oncol Cancer Med review; ESGO/ESTRO/ESP summary.
ЁЯУР FIGO 2023 STAGING
StageSpread
IConfined to the uterus and ovary (from memory)
IIInvades the cervical stroma; some aggressive types with invasion are also stage II (from memory)
IIILocal or regional spread: adnexa, serosa, vagina, parametria, pelvic or para-aortic nodes (from memory)
IVBladder or bowel mucosa, or distant spread (from memory)

FIGO 2023 combines stage with histology and molecular type, so stages are written such as IAmPOLEmut or IICmp53abn

Five-year survival by the older FIGO 2009 stages: IA about 90%, IB 78%, II 74%, IIIA 56%, IVA 22% (AAFP 2016). The new staging was not fetched in full.
STEP 4 · TREAT — surgery first, adjuvant by risk

Standard surgery: total hysterectomy with bilateral salpingo-oophorectomy, with pelvic washings and staging; laparoscopy has fewer complications than laparotomy

Sentinel lymph node mapping, or lymphadenectomy, establishes nodal status; nodal status drives the adjuvant choice

Adjuvant by risk group: low risk: none; intermediate: vaginal brachytherapy; high-intermediate: brachytherapy if nodes negative, external radiotherapy if nodes unknown; high: external radiotherapy with chemotherapy (ESGO/ESTRO/ESP)

Radiotherapy alone is reserved for women who cannot have surgery

Fertility-sparing treatment (progestins, levonorgestrel IUS) only for stage I grade 1 in a woman who wants a child; about 30% of grade 1 biopsies are upgraded, so hysterectomy is advised after childbearing

Recurrent or advanced disease: PD-1 immunotherapy may be considered, by molecular type (specialist decision)

ЁЯй║ FOLLOW-UP AND PREVENTION

Do not use Pap smears to monitor women treated for endometrial cancer (Choosing Wisely)

Follow-up visits, with a careful history and pelvic examination, and early review of any bleeding or pain (interval from memory)

Lynch syndrome: annual endometrial biopsy from age 35 is suggested but controversial; prophylactic hysterectomy can be considered after age 40 when the family is complete

Prevention: control weight, diabetes and blood pressure; add a progestogen to estrogen therapy in women with a uterus

Tamoxifen: no routine screening; any abnormal bleeding needs a full work-up

Reassuring a woman after one normal scan while bleeding continues

Trusting a negative Pipelle that was inadequate

Relying on endometrial thickness in a woman on tamoxifen

Treating abnormal bleeding in an obese or PCOS woman over 45 without sampling

Doing a simple hysterectomy for presumed benign disease and finding cancer, without staging (from memory)

Not asking about family history of colon or endometrial cancer, which points to Lynch syndrome

Memory Aid

BLEED

Five steps for postmenopausal bleeding and endometrial cancer.
B
Bleeding after menopause — always investigate
L
Look with ultrasound — 4 mm or less is reassuring, but watch for recurrence
E
Endometrial sample — Pipelle or hysteroscopy
E
Examine the tumour type — grade, p53, MMR, POLE
D
Define the stage and treat — surgery, then adjuvant by risk
Remember: early bleeding means early diagnosis; most women are found at stage I.

Cervical Cancer Is Preventable: Cervical Cancer Screening

Swaraj Hospital logo
SWARAJ HOSPITAL & RESEARCH INSTITUTE
BOLANGIR, ODISHA  •  OBSTETRICS & GYNAECOLOGY CLINICAL PATHWAY SERIES
Clinician Reference Infographic

Cervical Cancer Screening — HPV, VIA & the Pathway to Treatment

Cervical cancer can be prevented by finding and treating pre-cancer. This sheet gives who to screen and with which test, how the tests work, what to do with a positive result, treatment, and follow-up.

Cervical cancer is almost entirely caused by persistent infection with high-risk human papillomavirus (HPV); it develops slowly through pre-cancer stages, so screening can find and treat it before it becomes cancer

Worldwide in 2020, more than 500,000 women were diagnosed and about 342,000 died, mostly in poorer countries (WHO)

WHO now recommends an HPV DNA test as the preferred screening test, from age 30, repeated every 5 to 10 years; women living with HIV start at 25 and are screened every 3 to 5 years

India’s national framework screens all women aged 30 to 65 with VIA (visual inspection with acetic acid) once every 5 years, done by the ANM or staff nurse

Screening works only with follow-up: every positive woman must reach treatment

HPV vaccination of girls, with screening, is the route to eliminating cervical cancer

Screen every eligible woman, tell her the result in plain words, and make sure that a positive result leads to treatment.
ЁЯЪи DO NOT JUST SCREEN — INVESTIGATE OR REFER IF…
She has bleeding after sex, between periods or after menopause — examine the cervix and refer for colposcopy and biopsy; this is not screening (from memory)
The cervix looks irregular, hard, ulcerated or bleeds on touch — suspect cancer; biopsy and refer at once (from memory)
Offensive or blood-stained discharge, or pelvic or back pain — examine and refer (from memory)
A screening result is positive — do not let her go home without a plan: arrange triage or treatment and record the follow-up date
She is living with HIV or immunosuppressed — screen earlier and more often, and treat lesions with extra care
STEP 1 · WHO TO SCREEN — and with which test
ЁЯУЛ AGES, TESTS AND INTERVALS
GroupTestStart and repeat
General population (WHO 2021)HPV DNA test, with screen-and-treat or screen-triage-treatFrom 30 years; every 5 to 10 years
Women living with HIV (WHO 2021)HPV DNA test with a triage test if positiveFrom 25 years; every 3 to 5 years; retest sooner after a positive result or treatment
India, national frameworkVIA (visual inspection with acetic acid)All women 30–65 years; once every 5 years
Self-sampling (WHO)Self-collected sample for HPV DNA testingMay help more women to be screened; she needs clear instructions and support
Other tests such as the Pap smear (cytology) are used in many settings; they are not covered by the sources checked here. Stopping age, pregnancy and other details are from memory below.

HPV DNA test: detects high-risk HPV in a cervical or vaginal sample; objective, so it needs less interpretation than VIA or cytology, and is more effective and cost-effective, according to WHO

VIA: the cervix is washed with 3–5% acetic acid; a well-defined white patch near the squamocolumnar junction is a positive result (from memory)

Pap smear (cytology): cells are collected, stained and read by a cytologist, using the Bethesda system (from memory)

Triage after a positive HPV test: HPV 16/18 genotyping, VIA, cytology or colposcopy, according to what is available (from memory)

Colposcopy with biopsy confirms the grade of any lesion; histology gives the final diagnosis

STEP 2 · THE SCREENING PATHWAY — from the result to treatment
ЁЯзн WHAT TO DO AFTER THE FIRST TEST
Screening pathway: from the first test to treatmentWoman aged 30–65 (start at 25 if living with HIV)No symptoms: this is screening, not diagnosisHPV DNA test (WHO preferred)Where it is not available: VIA by a trained ANM or nurse (India)NegativeRescreen in 5–10 years (3–5 if HIV); India: 5 yearsPositive (or VIA positive)Triage test, or treat at onceIs she eligible for ablation?Whole lesion seen, no canal extension, no suspicion of cancerYes: ablationcryotherapy or thermal ablationNo, or suspect cancercolposcopy, biopsy, LEEP; referHPV DNA screening ages and intervals are from WHO 2021; the India VIA pathway is from the national framework.Eligibility details and triage tests are from memory.
STEP 3 · TREAT AND FOLLOW UP — never lose a positive woman

Ablative treatment (cryotherapy or thermal ablation) when the whole lesion is visible and does not extend into the cervical canal, and there is no suspicion of cancer (criteria from memory)

LEEP or cold-knife conisation when the lesion is larger, reaches into the canal, or ablation is not suitable (from memory)

Suspected invasive cancer: biopsy and refer to a cancer centre

In India, the medical officer at the PHC, CHC or district hospital manages VIA-positive women, with cryotherapy or colposcopy and biopsy, and the ANM and sub-centre staff arrange follow-up

Treat on the same visit where possible, so she is not lost (from memory)

ЁЯУЕ FOLLOW-UP AFTER TREATMENT

Test again after treatment to check that it worked; women living with HIV are retested sooner

Check healing, give written advice, and tell her to avoid sex and tampons for a few weeks (from memory)

Warning signs after treatment: heavy bleeding, fever, foul discharge, or severe pain; she should return at once (from memory)

Record every positive woman in a register and trace those who miss follow-up; a screening programme is effective only with an organised system of follow-up and management

Register families and list every woman over 30; the national framework plans population-based screening, with the ANM and ASHA on a fixed weekly screening day

Counsel her before the test: what it is, that it is quick and safe, that the result is private

Remove barriers: cost, distance, shyness, fear of the result, and the need for a woman provider (from memory)

Link screening with HPV vaccination of girls, and with family planning, antenatal and immunisation visits (from memory)

Use self-sampling where available to reach women who will not attend

ЁЯЫб️ PREVENTION: BEYOND SCREENING

HPV vaccination of girls before they become sexually active is part of the global strategy to eliminate cervical cancer; the 2030 targets are 90% vaccinated, 70% of women screened with a high-performance test, and 90% of women with cervical disease treated (vaccination target from memory)

Condom use, delaying the first sex, avoiding tobacco, and treating HIV all lower the risk (from memory)

Treating screening and diagnosis as the same thing: bleeding after sex needs a work-up

Letting a positive woman go home without a treatment or follow-up date

Screening too early, or too often, in low-risk women when resources are short (from memory)

Forgetting that women living with HIV need earlier and more frequent screening

Telling a woman that a negative HPV test means she will never need screening again

Breaking her privacy about the result

Memory Aid

SCREEN

Six steps for cervical cancer screening.
S
Start at 30 — at 25 if living with HIV
C
Choose the test — HPV DNA preferred; VIA in the national programme
R
Repeat on schedule — every 5–10 years (3–5 with HIV); every 5 years in India
E
Evaluate the positive — triage, colposcopy and biopsy
E
Eradicate the lesion — ablation or LEEP, same visit if possible
N
Note and follow up — register, recall, record
Remember: screening finds the pre-cancer; treatment and follow-up prevent the cancer.

About Me